Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Hudson

Showing results (371-380 of 400) with videos related to

Pageof 40
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancerW ten Bokkel Huinink, M Gore, J Carmichael, et al.
Stroke|May 12, 2016
Subfractions of High-Density Lipoprotein-Cholesterol and Carotid Intima-Media Thickness: The Northern Manhattan StudyEduard Tiozzo, Hannah Gardener, Barry I Hudson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancerG J Creemers, C J Gerrits, J H Schellens, et al.
Oncogene|September 27, 2016
Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasisT Kwak, K Drews-Elger, A Ergonul, et al.
Archives of Biochemistry and Biophysics|October 22, 2003
Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disordersBarry I Hudson, Loredana G Bucciarelli, Thoralf Wendt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)C J Gerrits, J H Schellens, H Burris, et al.
Archives of General Psychiatry|March 8, 2006
Binge-eating disorder as a distinct familial phenotype in obese individualsJames I Hudson, Justine K Lalonde, Judith M Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumorsC J Gerrits, H Burris, J H Schellens, et al.
Pageof 40

Showing results (371-380 of 400) with videos related to

Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancerW ten Bokkel Huinink, M Gore, J Carmichael, et al.
Stroke|May 12, 2016
Subfractions of High-Density Lipoprotein-Cholesterol and Carotid Intima-Media Thickness: The Northern Manhattan StudyEduard Tiozzo, Hannah Gardener, Barry I Hudson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancerG J Creemers, C J Gerrits, J H Schellens, et al.
Oncogene|September 27, 2016
Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasisT Kwak, K Drews-Elger, A Ergonul, et al.
Archives of Biochemistry and Biophysics|October 22, 2003
Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disordersBarry I Hudson, Loredana G Bucciarelli, Thoralf Wendt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)C J Gerrits, J H Schellens, H Burris, et al.
Archives of General Psychiatry|March 8, 2006
Binge-eating disorder as a distinct familial phenotype in obese individualsJames I Hudson, Justine K Lalonde, Judith M Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumorsC J Gerrits, H Burris, J H Schellens, et al.
Pageof 40